{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:07:28Z","timestamp":1781327248332,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canrad.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:24:34Z","timestamp":1724372674000},"page":"633-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5263-1652","authenticated-orcid":false,"given":"L\u00e9a","family":"Marxgut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Desagneaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Mouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Laramas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Verry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.03.006_bib0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2024.03.006_bib0165","unstructured":"SEER [Internet]. Melanoma of the skin - Cancer Stat Facts. [Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html (consulted 6 Jul 2023)]."},{"key":"10.1016\/j.canrad.2024.03.006_bib0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.canrad.2024.03.006_bib0175","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0180","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.03.006_bib0190","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.03.006_bib0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0200","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0205","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0210","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u00a0\u2013\u00a0Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2024.03.006_bib0215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes","volume":"248","author":"van Akkooi","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.canrad.2024.03.006_bib0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.canrad.2024.03.006_bib0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2006.10.001","article-title":"A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06","volume":"81","author":"Burmeister","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0230","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.03.006_bib0235","first-page":"XC01","article-title":"Toxicity profile of IMRT vs. 3D-CRT in head and neck cancer: a retrospective study","volume":"10","author":"Ghosh","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.canrad.2024.03.006_bib0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.canrad.2016.05.011","article-title":"Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: a randomized prospective study","volume":"20","author":"Naik","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2024.03.006_bib0245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0250","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1245\/s10434-020-09384-8","article-title":"Adjuvant radiation therapy for clinical stage III melanoma in the modern therapeutic era","volume":"28","author":"Straker","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0255","doi-asserted-by":"crossref","first-page":"e006629","DOI":"10.1136\/jitc-2022-006629","article-title":"Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy","volume":"11","author":"Bhave","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2024.03.006_bib0260","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.03.006_bib0265","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0270","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.03.006_bib0275","doi-asserted-by":"crossref","first-page":"TPS9605","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605","article-title":"The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0280","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2024.03.006_bib0285","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canrad.2024.03.006_bib0290","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canrad.2024.03.006_bib0295","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.adro.2018.08.021","article-title":"Generating antitumor immunity by targeted radiation therapy: role of dose and fractionation","volume":"3","author":"Ko","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2024.03.006_bib0300","doi-asserted-by":"crossref","first-page":"e000395","DOI":"10.1136\/jitc-2019-000395","article-title":"Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG","volume":"8","author":"Knispel","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2024.03.006_bib0305","doi-asserted-by":"crossref","first-page":"vdac132","DOI":"10.1093\/noajnl\/vdac132","article-title":"The abscopal effect: systematic review in patients with brain and spine metastases","volume":"4","author":"Pangal","year":"2022","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.canrad.2024.03.006_bib0310","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:16:50Z","timestamp":1733055410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1278321824000994"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.03.006","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}